Biologic agents in rheumatology: Unmet issues after 200 trials and $200 billion sales

Nature Reviews Rheumatology

Volumn 9, Issue 11, 2013, Pages 665-673

  Ioannidis, John P A ^a   Karassa, Fotini B ^b   Druyts, Eric ^c   Thorlund, Kristian ^a   Mills, Edward J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF IOANNINA   (Greece)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; BRIAKINUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; ETRETIN; FUMATIC ACID ESTER DERIVATIVE; GOLIMUMAB; GUSELKUMAB; INFLIXIMAB; IXEKIZUMAB; METHOTREXATE; MK 2222; PAMIDRONIC ACID; PLACEBO; RITUXIMAB; SECUKINUMAB; TOCILIZUMAB; TOFACITINIB; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; USTEKINUMAB;

ANKYLOSING SPONDYLITIS; CANCER RISK; COMPARATIVE STUDY; DRUG COST; DRUG DESIGN; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG RESEARCH; EVIDENCE BASED MEDICINE; FOLLOW UP; HEALTH CARE NEED; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; META ANALYSIS (TOPIC); NONHUMAN; PHOTOTHERAPY; PRESCRIPTION; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPONSIBILITY; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMATIC REVIEW (TOPIC); TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

BIOLOGICAL FACTORS; COMMERCE; COST-BENEFIT ANALYSIS; HUMANS; RHEUMATIC DISEASES; RHEUMATOLOGY;

EID: 84887134614     PISSN: 17594790     EISSN: 17594804     Source Type: Journal    
DOI: 10.1038/nrrheum.2013.134     Document Type: Review

References (47)

1. Helmick, C. G. et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part 1. Arthritis Rheum. 58, 15-25 (2008).
2. Lawrence, R. C. et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part 2. Arthritis Rheum. 58, 26-35 (2008).
3. Drugs information online. U. S. Pharmaceutical Sales-2012. Top 100 Drugs for 2012 by Sales [online], http://www.drugs.com/stats/top100/2012/sales (2013).
4. Khan, N. A., Lombeida, J. I., Singh, M., Spencer, H. J. & Torralba, K. D. Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis. Arthritis Rheum. 64, 2059-2067 (2012).
5. Bourgeois, F. T., Murthy, S. & Mandl, K. D. Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann. Intern. Med. 153, 158-166 (2010).
6. Dwan, K. et al. Systematic review of the empirical evidence of study publication bias and outcome reporting bias. PLoS ONE 3, e3081 (2008).
7. Gøtzche, P. C. Reference bias in reports of drug trials. Br. Med. J. (Clin. Res. Ed.) 295, 654-656 (1987).
8. Gøtzche, P. C. Multiple publication of reports of drug trials. Eur. J. Clin. Pharmacol. 36, 429-432 (1989).
9. Thorlund, K., Druyts, E., Aviña-Zubieta, J. A. & Mills, E. J. Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis. Biologics 6, 417-427 (2012).
10. Chan, A. W. & Altman, D. G. Identifying outcome reporting bias in randomised trials on PubMed: review of publications and survey of authors. BMJ 330, 753 (2005).
11. Chan, A. W., Krieza-Jeri?, K., Schmid, I. & Altman, D. G. Outcome reporting bias in randomized trials funded by the Canadian Institutes of Health Research. CMAJ 171, 735-740 (2004). (Pubitemid 39319090)
12. Chan, A. W., Hróbjartsson, A., Haahr, M. T., Gøtzche, P. C. & Altman, D. G. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published article. JAMA 291, 2457-2465 (2004). (Pubitemid 38669189)
13. Thorlund, K., Druyts, E., Aviña-Zubieta, J. A., Wu, P. & Mills, E. J. Why the findings of published multiple treatment comparison meta-analyses of biologic treatments for rheumatoid arthritis are different: an overview of recurrent methodological shortcomings. Ann. Rheum. Dis. http://dx.doi.org/10. 1136/annrheumdis-2012-201574.
14. Gøtzche, P. C. Reporting of outcomes in arthritis trials measured on ordinal and interval scales is inadequate in relation to meta-analysis. Ann. Rheum. Dis. 60, 349-352 (2001).
15. Gøtzche, P. C. Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials. J. Clin. Epidemiol. 42, 1313-1318 (1990).
16. Gøtzche, P. C. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control. Clin. Trials 10, 31-56 (1989).
17. Simsek, I. & Yazici, Y. Incomplete reporting of recruitment information in clinical trials of biologic agents for the treatment of rheumatoid arthritis: a review. Arthritis Care Res. (Hoboken) 64, 1611-1616 (2012).
18. Sokka, T. & Pincus, T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor ? agents in rheumatoid arthritis. Arthritis Rheum. 28, 313-318 (2003). (Pubitemid 36277997)
19. Guyot, P. et al. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United Kingdom. J. Rheumatol. 39, 1198-1206 (2012).
20. Panagiotou, O. A., Contopoulos-Ioannidis, D. G. & Ioannidis, J. P. Comparative effect sizes in randomised trials from less developed and more developed countries: meta-epidemiological assessment. BMJ 346, F707 (2013).
21. Putrik, P. et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann. Rheum. Dis. http://dx.doi.org/10.1136/ annrheumdis-2012-202603.
22. Estellat, C. & Ravaud, P. Lack of head-to-head trials and fair control arms randomized controlled trials of biologic treatment for rheumatoid arthritis. Arch. Intern. Med. 172, 237-244 (2012).
23. Ioannidis, J. P. & Karassa, F. B. The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence. BMJ 341, c4875 (2010).
24. Lexchin, J., Bero, L. A., Djulbegovic, B. & Clark, O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326, 1167-1170 (2003). (Pubitemid 36649048)
25. Lathyris, D. N., Patsopoulos, N., Salanti, G. & Ioannidis, J. P. Industry sponsorship and selection of comparators in randomized clinical trials. Eur. J. Clin. Invest. 40, 172-182 (2010).
26. Paul, J. R. & Ranganathan, P. Clinical trials in rheumatoid arthritis: a status report from the ClinicalTrials.gov website. Rheumatol. Int. 32, 1831-1835 (2012).
27. Sanderson, T., Morris, M., Calnan, M., Richards, P. & Hewlett, S. What outcomes from pharmacologic treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set. Arthritis Care Res. (Hoboken) 62, 640-646 (2010).
28. Wells, G., Li, T., Maxwell, L., Maclean, R. & Tugwell, P. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. Ann. Rheum. Dis. 67, 260-265 (2008). (Pubitemid 351183320)
29. Roundtree, A. K. et al. Poor reporting of search strategy and conflict of interest in over 250 narrative and systematic reviews of two biologic agents in arthritis: a systematic review. J. Clin. Epidemiol. 62, 128-137 (2009).
30. Jørgensen, A. W., Hilden, J. & Gøtzche, P. C. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ 333, 782 (2006).
31. Aletaha, D. et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62, 2569-2581 (2010).
32. Aletaha, D. et al. Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations. Arthritis Rheum. 59, 1371-1377 (2008).
33. Funovits, J. et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. Ann. Rheum. Dis. 69, 1589-1595 (2010).
34. Lopez-Olivo M. A. et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 308, 898-908 (2012).
35. Thompson, A. E., Rieder, S. W. & Pope, J. E. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. Arthritis Rheum. 63, 1479-1485 (2011).
36. Leombruno, J. P., Einarson, T. R. & Keystone, E. C. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann. Rheum. Dis. 68, 1136-1145 (2009).
37. Bongartz, T. et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-2285 (2006). (Pubitemid 43736578)
38. Singh, J. A. et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst. Rev. Issue 2. Art. No.: CD008794 (2011).
39. Yazici, Y. & Yazici, H. A survey of inclusion of the time element when reporting adverse effects in randomised controlled trials of cyclo-oxygenase-2 and tumour necrosis factor ? inhibitors. Ann. Rheum. Dis. 66, 124-127 (2007). (Pubitemid 46044872)
40. Smolen, J. S. et al. Recommendations for an update of 2003 European regulatory requirements for registration of drugs to be used in the treatment of RA. Curr. Med. Res. Opin. 27, 315-325 (2011).
41. Ioannidis, J. P. Mega-trials for blockbusters. JAMA 309, 239-240 (2013).
42. Wolfe, F. & Michaud, K. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness. Rheumatology (Oxford) 44 (Suppl. 4), iv18-iv22 (2006). (Pubitemid 41724324)
43. Yazici, H. Beware of registries for their biases. Bull. NYU Hosp. Jt Dis. 70, 95-98 (2012).
44. The AllTrials Petition. All Trials Registered | All Results Reported [online], http://www.alltrials.net/ (2013).
45. Doshi, P. & Jefferson, T. The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer. JAMA Intern. Med. 173, 380-382 (2013).
46. Doshi, P. & Jefferson, T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open 3, e002496 (2013).
47. O'Dell, J. R. et al. Therapies for active rheumatoid arthritis after methotrexate failure. N. Engl. J. Med. 369, 307-318 (2013).